Editorial Expression of Concern: Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia

Addendum to: *Nature Medicine*
https://doi.org/10.1038/nm1418.
Published online 11 June 2006.

https://doi.org/10.1038/s41591-023-02757-y

Published online: 19 December 2023

Chang-Gyu Hahn, Hoau-Yan Wang, Dan-Sung Cho, Konrad Talbot, Raquel E Gur, Wade H Berrettini, Kalindi Bakshi, Joshua Kamins, Karin E Borgmann-Winter, Steven J Siegel, Robert J Gallop & Steven E Arnold

The Editors are issuing an editorial expression of concern to alert readers that concerns have been raised regarding the western blot images presented in some of the figures in this article[1]. Specifically, a number of blots in Figs. 2a and 4a and Supplementary Figs. 2 and 3 have unusual artifacts (straight line breaks in the background or blank areas). Additionally, some bands in Fig. 2 appear to be duplicated in Supplementary Fig. 1.

In response, the authors have argued that the duplication between Fig. 2 and Supplementary Fig. 1 was intentional and designed to illustrate differences between experimental and control groups, and to demonstrate the experimental workflow, respectively. The artifacts in the other blots are thought to have been caused by increased brightness and contrast for improved blot presentation. The authors have also stated that they no longer have access to the original gel images due to the age of the study.

Based on the number and nature of these concerns, the Editors advise the readers to interpret the presented data with caution.

Dan-Sung Cho agrees to this editorial expression of concern. Chang-Gyu Hahn, Steven Siegel, Raquel Gur, Steven Arnold, Wade Berrettini, Hoau-Yan Wang, Karin Borgmann-Winter and Robert Gallop do not agree to this editorial expression of concern. Konrad Talbot, Kalindi Bakshi and Joshua Kamins have not responded to any correspondence from the editor or publisher about this editorial expression of concern.

References

1. Hahn, C.-G. et al. Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia. *Nat. Med.* **12**, 824–828 (2006).